Title
Feasibility of a streamlined tuberculosis diagnosis & treatment initiation strategy
Date Issued
01 July 2017
Access level
open access
Resource Type
journal article
Author(s)
Shete P.B.
Nalugwa T.
Farr K.
Ojok C.
Nantale M.
Howlett P.
Haguma P.
Ochom E.
Mugabe F.
Joloba M.
Chaisson L.H.
Dowdy D.W.
Davis J.L.
Katamba A.
Cattamanchi A.
London School of Hygiene and Tropical Medicine
Publisher(s)
International Union against Tubercul. and Lung Dis.
Abstract
OBJECTIVE : To assess the feasibility of a streamlined strategy for improving tuberculosis (TB) diagnostic evaluation and treatment initiation among patients with presumed TB. DESIGN: Single-Arm interventional pilot study at five primary care health centers of a streamlined, SInglesaMPLE (SIMPLE) TB diagnostic evaluation strategy: 1) examination of two smear results from a single spot sputum specimen using light-emitting diode fluorescence microscopy, and 2) daily transportation of smearnegative sputum samples to Xpertw MTB/RIF testing sites. RESULT S : Of 1212 adults who underwent sputum testing for TB, 99.6% had two smears examined from the spot sputum specimen. Sputum was transported for Xpert testing within 1 clinic day for 83% (907/1091) of the smear-negative patients. Of 157 (13%) patients with bacteriologically positive TB, 116 (74%) were identified using sputum smear microscopy and 41 (26%) using Xpert testing of smear-negative samples. Anti-Tuberculosis treatment was initiated in 142 (90%) patients with bacteriologically positive TB, with a median time to treatment of 1 day for smear-positive patients and 6 days for smear-negative, Xpert-positive patients. CONCLUS ION: The SIMPLE TB strategy led to successful incorporation of Xpert testing and rapid treatment initiation in the majority of patients with bacteriologically confirmed TB in a resource-limited setting.
Start page
746
End page
752
Volume
21
Issue
7
Language
English
OCDE Knowledge area
Salud pública, Salud ambiental Sistema respiratorio
Scopus EID
2-s2.0-85021125192
PubMed ID
Source
International Journal of Tuberculosis and Lung Disease
ISSN of the container
10273719
Sponsor(s)
National Heart, Lung, and Blood Institute - R01HL130192 -NHLBI The study was supported by Medical Research Council/Wellcome Trust/UK Department for International Development (London, UK) Joint Funded Initiative Development Grant (MR/M017362/1, DM) and R01 HL130192 (AC) from the US National Institutes of Health (NIH; Bethesda, MD, USA). In addition, PS received support from NIH T32 5T32HL007185-35.
Sources of information: Directorio de Producción Científica Scopus